In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...

Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

Early and sustained adherence to antimalarials may help prevent RA and SLE disease flares, cardiovascular complications, and reduce future hospital use and costs.

A study identified an accurate approach to measuring disease activity in patients with systemic lupus erythematosus (SLE), which is crucial for clinical management.

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.

Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...